Department of Endocrinology, St Bartholomew's Hospital, London, UK.
Horm Res Paediatr. 2010;73(2):135-9. doi: 10.1159/000277659. Epub 2010 Feb 9.
BACKGROUND/AIMS: To describe the management of a subject with multiple chromaffin tumours found to have a novel succinate dehydrogenase D (SDHD) mutation.
A 15-year-old boy with marked hypertension was found to have elevated urinary catecholamines and initial imaging thought to represent bilateral adrenal phaeochromocytomas. An adrenal venous catheter was required to clarify a right adrenal phaeochromocytoma and a left abdominal paraganglioma, distinct from the left adrenal gland. Excision of these tumours, with preservation of the left adrenal gland, provided a cure for this subject without the need for lifelong steroid replacement. Genetic analysis revealed a novel SDHD mutation (c. 169 + 1 G>A) which was shown to result in loss of the 5' splice site and exclusion of exon 2 during splicing. This suggests the likely pathogenicity of this mutation. Disease surveillance in this subject and genetic screening of first degree relatives is ongoing.
Genetic testing should be considered in all subjects presenting with a chromaffin tumour. In certain circumstances an adrenal venous sampling catheter for catecholamines may clarify diagnostic uncertainty. The complex management issues raised in the care of these subjects requires the involvement of a multidisciplinary team with the relevant expertise.
背景/目的:描述一名患有多种嗜铬细胞瘤的患者的治疗方法,该患者被发现存在一种新的琥珀酸脱氢酶 D(SDHD)突变。
一名 15 岁男孩患有明显的高血压,其尿儿茶酚胺升高,最初的影像学检查提示双侧肾上腺嗜铬细胞瘤。需要进行肾上腺静脉导管检查以明确右肾上腺嗜铬细胞瘤和左腹部副神经节瘤,这些肿瘤与左肾上腺不同。切除这些肿瘤(保留左肾上腺)治愈了该患者,无需终身类固醇替代治疗。基因分析显示一种新的 SDHD 突变(c.169+1G>A),导致 5'剪接位点缺失,并在剪接过程中排除外显子 2。这表明该突变可能具有致病性。该患者正在进行疾病监测和一级亲属的基因筛查。
所有患有嗜铬细胞瘤的患者均应考虑进行基因检测。在某些情况下,用于儿茶酚胺的肾上腺静脉采样导管可澄清诊断的不确定性。这些患者的治疗需要多学科团队的参与,包括相关专业知识。